These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10586496)

  • 1. Structure-activity relationships of RGD mimetics as fibrinogen-receptor antagonists.
    Miyashita M; Akamatsu M; Ueno H; Nakagawa Y; Nishimura K; Hayashi Y; Sato Y; Ueno T
    Biosci Biotechnol Biochem; 1999 Oct; 63(10):1684-90. PubMed ID: 10586496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA; Bozarth JM; Naik UP; Slee A
    Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist.
    Hayashi Y; Katada J; Sato Y; Igarashi K; Takiguchi Y; Harada T; Muramatsu M; Yasuda E; Uno I
    Bioorg Med Chem; 1998 Mar; 6(3):355-64. PubMed ID: 9568289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional quantitative structure-activity relationship analyses of RGD mimetics as fibrinogen receptor antagonists.
    Miyashita M; Akamatsu M; Hayashi Y; Ueno T
    Bioorg Med Chem Lett; 2000 May; 10(9):859-63. PubMed ID: 10853647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action.
    Yang G; Zhu H; Zhao M; Wu J; Wang Y; Wang Y; Zheng M; Chen M; Liu J; Peng S
    Mol Biosyst; 2012 Oct; 8(10):2672-9. PubMed ID: 22801714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
    Andronati SA; Karaseva TL; Krysko AA
    Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.
    Manaka A; Sato M; Aoki M; Tanaka M; Ikeda T; Toda Y; Yamane Y; Nakaike S
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1031-5. PubMed ID: 11327582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.
    Wittig K; Rothe G; Schmitz G
    Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-platelet peptide (Z4A5) potential for glycoprotein IIb/IIIa inhibits platelet aggregation.
    Li YX; Sun Q; Zhang H; Ren ST; Liao YR; Wang Y; Shen XL; Wang B
    Thromb Res; 2012 May; 129(5):e217-22. PubMed ID: 22445430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
    Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
    J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists.
    Robarge KD; Dina MS; Somers TC; Lee A; Rawson TE; Olivero AG; Tischler MH; Webb RR; Weese KJ; Aliagas I; Blackburn BK
    Bioorg Med Chem; 1998 Dec; 6(12):2345-81. PubMed ID: 9925295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo.
    Murphy NP; Pratico D; Fitzgerald DJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):945-51. PubMed ID: 9694954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.
    Krysko AA; Samoylenko GV; Polishchuk PG; Fonari MS; Kravtsov VCh; Andronati SA; Kabanova TA; Lipkowski J; Khristova TM; Kuz'min VE; Kabanov VM; Krysko OL; Varnek AA
    Bioorg Med Chem; 2013 Aug; 21(15):4646-61. PubMed ID: 23757209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
    Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RGD mimetics containing phthalimidine fragment as novel ligands of fibrinogen receptor.
    Krysko AA; Samoylenko GV; Polishchuk PG; Andronati SA; Kabanova TA; Khristova TM; Kuz'min VE; Kabanov VM; Krysko OL; Varnek AA; Grygorash RY
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5971-4. PubMed ID: 21852128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies.
    Pearson DA; Lister-James ; McBride WJ; Wilson DM; Martel LJ; Civitello ER; Dean RT
    J Med Chem; 1996 Mar; 39(7):1372-82. PubMed ID: 8691467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.